Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization-Reference-Cited by-同舟云学术

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization

Published:2021-03 Issue: Volume:Volume 17 Page:223-232
ISSN:1178-203X
Container-title:Therapeutics and Clinical Risk Management
language:en
Short-container-title:TCRM

Author:

Simonetti Oriana,Rizzetto Giulio^ORCID,Molinelli Elisa,Cirioni Oscar,Offidani Annamaria

Publisher

Informa UK Limited

Subject

Chemical Health and Safety,Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,Safety Research,General Medicine

Reference59 articles.

1. Dalvance prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021883s000lblpdf. Accessed November 10, 2020.

2. Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide

3. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016)

4. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections

5. Current trends in the real-life use of dalbavancin: report of a study panel

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI;Global and Regional Health Technology Assessment;2024-07-29

2. Prescriptive appropriateness of dalbavancin in acute bacterial skin and skin structure infections in adults: an integrated approach between clinical profile, patient- and health system-related factors and focus on environmental impact;Frontiers in Antibiotics;2024-04-24

3. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service;Infection;2024-01-02

4. Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel;International Journal of Antimicrobial Agents;2023-11

5. Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection;BMC Infectious Diseases;2023-10-19